Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4+ T Cells

The inherent risks associated with vector insertion in gene therapy need to be carefully assessed. We analyzed the genome-wide distributions of Sleeping Beauty (SB) and piggyBac (PB) transposon insertions as well as MLV retrovirus and HIV lentivirus insertions in human CD4+ T cells with respect to a panel of 40 chromatin states. The distribution of SB transposon insertions displayed the least deviation from random, while the PB transposon and the MLV retrovirus showed unexpected parallels across all chromatin states. Both MLV and PB insertions are enriched at transcriptional start sites (TSSs) and co-localize with BRD4-associated sites. We demonstrate physical interaction between the PB transposase and bromodomain and extraterminal domain proteins (including BRD4), suggesting convergent evolution of a tethering mechanism that directs integrating genetic elements into TSSs. We detect unequal biases across the four systems with respect to targeting genes whose deregulation has been previously linked to serious adverse events in gene therapy clinical trials. The SB transposon has the highest theoretical chance of targeting a safe harbor locus in the human genome. The data underscore the significance of vector choice to reduce the mutagenic load on cells in clinical applications.

[1]  J. Choi,et al.  Genome-wide reorganization of histone H2AX toward particular fragile sites on cell activation , 2013, Nucleic acids research.

[2]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[3]  Dustin E. Schones,et al.  Genomic Profiling of HMGN1 Reveals an Association with Chromatin at Regulatory Regions , 2010, Molecular and Cellular Biology.

[4]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[5]  Michael Q. Zhang,et al.  Combinatorial patterns of histone acetylations and methylations in the human genome , 2008, Nature Genetics.

[6]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[7]  D. Steinemann,et al.  Gene therapy for Wiskott-Aldrich syndrome-long - Term efficacy and genotoxicity (Science Translational Medicine) , 2014 .

[8]  Brendan B. Larsen,et al.  Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection , 2014, Science.

[9]  F. Bushman,et al.  Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction , 2014, Nucleic acids research.

[10]  T. Schulz,et al.  WHAT do viruses BET on? , 2010, Frontiers in bioscience.

[11]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[12]  Z. Izsvák,et al.  Retargeting transposon insertions by the adeno-associated virus Rep protein , 2012, Nucleic acids research.

[13]  P. Howley,et al.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Interacts with Bromodomain Protein Brd4 on Host Mitotic Chromosomes , 2006, Journal of Virology.

[14]  K. Hoe,et al.  Integration Profiling of Gene Function With Dense Maps of Transposon Integration , 2013, Genetics.

[15]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[16]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[17]  Z. Izsvák,et al.  The expanding universe of transposon technologies for gene and cell engineering , 2010, Mobile DNA.

[18]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[19]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[20]  K. Struhl,et al.  Determinants of nucleosome positioning , 2013, Nature Structural &Molecular Biology.

[21]  Alfred L George,et al.  PiggyBac transposon-mediated gene transfer in human cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Boeke,et al.  Transposon-mediated genome manipulation in vertebrates , 2009, Nature Methods.

[24]  A. Spradling,et al.  The Drosophila Gene Disruption Project: Progress Using Transposons With Distinctive Site Specificities , 2011, Genetics.

[25]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[26]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[27]  G. Chaconas,et al.  Structural aspects of a higher order nucleoprotein complex: induction of an altered DNA structure at the Mu‐host junction of the Mu type 1 transpososome. , 1991, The EMBO journal.

[28]  David A. Williams,et al.  Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Suresh Cuddapah,et al.  Pol II and its associated epigenetic marks are present at pol III-transcribed non-coding RNA genes , 2010, Nature Structural &Molecular Biology.

[30]  Alfred L George,et al.  Manipulating piggyBac transposon chromosomal integration site selection in human cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  Z. Izsvák,et al.  Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  Z. Weng,et al.  High-Resolution Mapping and Characterization of Open Chromatin across the Genome , 2008, Cell.

[33]  Paul Shinn,et al.  A role for LEDGF/p75 in targeting HIV DNA integration , 2005, Nature Medicine.

[34]  S. Hughes,et al.  Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.

[35]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[36]  Frederic D Bushman,et al.  Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  K. Cermakova,et al.  BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements , 2014, Molecular therapy. Nucleic acids.

[38]  M. Johnston,et al.  “Calling Cards” for DNA-Binding Proteins in Mammalian Cells , 2012, Genetics.

[39]  T. Schulz,et al.  A Structural Basis for BRD2/4-Mediated Host Chromatin Interaction and Oligomer Assembly of Kaposi Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus LANA Proteins , 2013, PLoS pathogens.

[40]  Z. Izsvák,et al.  Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[42]  Shawn M. Burgess,et al.  High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals , 2005, Molecular and Cellular Biology.

[43]  Z. Izsvák,et al.  Nonviral gene delivery with the sleeping beauty transposon system. , 2011, Human gene therapy.

[44]  Andreas D. Baxevanis,et al.  MLV integration site selection is driven by strong enhancers and active promoters , 2014, Nucleic acids research.

[45]  Nathaniel D. Heintzman,et al.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.

[46]  N. Craig,et al.  piggyBac can bypass DNA synthesis during cut and paste transposition , 2008, The EMBO journal.

[47]  R. Plasterk,et al.  Involvement of a Bifunctional, Paired-like DNA-binding Domain and a Transpositional Enhancer in Sleeping BeautyTransposition* , 2002, The Journal of Biological Chemistry.

[48]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[49]  Nir Friedman,et al.  High-resolution nucleosome mapping reveals transcription-dependent promoter packaging. , 2010, Genome research.

[50]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[51]  A. Bradley,et al.  Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons , 2009, Genesis.

[52]  T. Mikkelsen,et al.  The NIH Roadmap Epigenomics Mapping Consortium , 2010, Nature Biotechnology.

[53]  Steven J. M. Jones,et al.  Bromodomain-containing Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells* , 2012, The Journal of Biological Chemistry.

[54]  T. Schulz,et al.  Brd2/RING3 Interacts with a Chromatin-Binding Domain in the Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 (LANA-1) That Is Required for Multiple Functions of LANA-1 , 2005, Journal of Virology.

[55]  R. Harshey,et al.  The same two monomers within a MuA tetramer provide the DDE domains for the strand cleavage and strand transfer steps of transposition , 1998, The EMBO journal.

[56]  F. Mavilio,et al.  Genetic modification of somatic stem cells , 2008, EMBO reports.

[57]  K. Kawakami,et al.  Comparative analysis of transposable element vector systems in human cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[59]  Harjeet Singh,et al.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.

[60]  Michel Sadelain,et al.  Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.

[61]  K. Ozato,et al.  Interaction of Bovine Papillomavirus E2 Protein with Brd4 Stabilizes Its Association with Chromatin , 2005, Journal of Virology.

[62]  A. Schambach,et al.  Gene therapy: X-SCID transgene leukaemogenicity , 2006, Nature.

[63]  K. Ozato,et al.  The Mitotic Chromosome Binding Activity of the Papillomavirus E2 Protein Correlates with Interaction with the Cellular Chromosomal Protein, Brd4 , 2005, Journal of Virology.

[64]  Dustin E. Schones,et al.  Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes , 2009, Cell.

[65]  M. Hansmann,et al.  Resistance of mature T cells to oncogene transformation. , 2008, Blood.

[66]  L. Wessels,et al.  Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions , 2008, Nature.

[67]  W. Leonard,et al.  Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages , 2011, Nature Immunology.

[68]  B. Langmead,et al.  Aligning Short Sequencing Reads with Bowtie , 2010, Current protocols in bioinformatics.

[69]  Michael Rothe,et al.  Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.

[70]  D. Largaespada,et al.  A transposon and transposase system for human application. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  F. Bushman,et al.  The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. , 2013, Cell reports.

[72]  S. Ekker,et al.  Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  Frederic D. Bushman,et al.  Gammaretroviral Integration into Nucleosomal Target DNA In Vivo , 2011, Journal of Virology.

[74]  L. Frappier,et al.  The EBNA1 Protein of Epstein-Barr Virus Functionally Interacts with Brd4 , 2008, Journal of Virology.

[75]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[76]  Wei Chen,et al.  Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  A. Schambach,et al.  Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration , 2013, Journal of Virology.

[78]  T. Baker,et al.  Organization and dynamics of the Mu transpososome: recombination by communication between two active sites. , 1999, Genes & development.

[79]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[80]  Kosuke Yusa,et al.  The piggyBac Transposon Displays Local and Distant Reintegration Preferences and Can Cause Mutations at Noncanonical Integration Sites , 2013, Molecular and Cellular Biology.

[81]  Dustin E. Schones,et al.  Dynamic Regulation of Nucleosome Positioning in the Human Genome , 2008, Cell.

[82]  A. Schambach,et al.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  F. Bushman,et al.  A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture , 2012, Proceedings of the National Academy of Sciences.

[84]  G. Chaconas,et al.  Transposition of phage Mu DNA. , 1996, Current topics in microbiology and immunology.

[85]  Steven J. Kass,et al.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. , 2011, Current gene therapy.

[86]  Keji Zhao,et al.  Dynamic regulation of epigenomic landscapes during hematopoiesis , 2013, BMC Genomics.

[87]  L. Mularoni,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:DNA transposon Hermes inserts into DNA in nucleosome-free regions in vivo , 2010 .

[88]  S. Montaño,et al.  The Mu transpososome structure sheds light on DDE recombinase evolution , 2012, Nature.

[89]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[90]  F. Bushman,et al.  BET proteins promote efficient murine leukemia virus integration at transcription start sites , 2013, Proceedings of the National Academy of Sciences.

[91]  Rishi Matadeen,et al.  Structural basis for retroviral integration into nucleosomes , 2015, Nature.

[92]  Wilma K Olson,et al.  Target-site preferences of Sleeping Beauty transposons. , 2005, Journal of molecular biology.

[93]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[94]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[95]  Daniel F Voytas,et al.  Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. , 2002, Journal of molecular biology.

[96]  T. Schulz,et al.  Kaposi's Sarcoma-Associated Herpesvirus LANA-1 Interacts with the Short Variant of BRD4 and Releases Cells from a BRD4- and BRD2/RING3-Induced G1 Cell CycleArrest , 2006, Journal of Virology.

[97]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[98]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[99]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[100]  Alistair G. Rust,et al.  Chromatin Landscapes of Retroviral and Transposon Integration Profiles , 2014, PLoS genetics.